Nektar Therapeutics (NKTR) said Thursday that its experimental cancer treatment, NKTR-255, combined with durvalumab, sped up the recovery of immune cells in patients who had completed radiation therapy.
The interim analysis of the phase 2 study showed that NKTR-255 reversed radiation-induced lymphopenia in patients with locally advanced non-small cell lung cancer, according to the company.
Nektar said NKTR-255, when combined with durvalumab after radiation therapy, significantly improved the recovery of lymphocytes after 8 weeks compared to patients who received radiation therapy alone or radiation therapy with durvalumab.
Shares of the company were down 2.1% in recent trading.
Price: 1.37, Change: -0.02, Percent Change: -1.44
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。